| Literature DB >> 28559357 |
Aaron Seo1,2, Miri Ben-Harosh3, Mehtap Sirin4, Jerry Stein5,6, Orly Dgany6,7, Joseph Kaplelushnik3, Manfred Hoenig4, Ulrich Pannicke8, Myriam Lorenz8, Klaus Schwarz8,9, Clemens Stockklausner10, Tom Walsh1,2, Suleyman Gulsuner1,2, Ming K Lee1,2, Anoop Sendamarai11, Marilyn Sanchez-Bonilla12, Mary-Claire King1,2, Holger Cario4, Andreas E Kulozik10, Klaus-Michael Debatin4, Ansgar Schulz4, Hannah Tamary6,7,13, Akiko Shimamura12.
Abstract
We report 5 individuals in 3 unrelated families with severe thrombocytopenia progressing to trilineage bone marrow failure (BMF). Four of the children received hematopoietic stem cell transplants and all showed poor graft function with persistent severe cytopenias even after repeated transplants with different donors. Exome and targeted sequencing identified mutations in the gene encoding thrombopoietin (THPO): THPO R99W, homozygous in affected children in 2 families, and THPO R157X, homozygous in the affected child in the third family. Both mutations result in a lack of THPO in the patients' serum. For the 2 surviving patients, improvement in trilineage hematopoiesis was achieved following treatment with a THPO receptor agonist. These studies demonstrate that biallelic loss-of-function mutations in THPO cause BMF, which is unresponsive to transplant due to a hematopoietic cell-extrinsic mechanism. These studies provide further support for the critical role of the MPL-THPO pathway in hematopoiesis and highlight the importance of accurate genetic diagnosis to inform treatment decisions for BMF.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28559357 PMCID: PMC5561901 DOI: 10.1182/blood-2017-02-768036
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113